Jones Financial Companies Lllp Boosts Holdings in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Jones Financial Companies Lllp grew its position in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 195.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,176 shares of the company’s stock after purchasing an additional 1,440 shares during the period. Jones Financial Companies Lllp owned approximately 0.06% of Invesco Pharmaceuticals ETF worth $180,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PJP. Joseph Group Capital Management raised its stake in shares of Invesco Pharmaceuticals ETF by 16.0% during the third quarter. Joseph Group Capital Management now owns 15,080 shares of the company’s stock valued at $1,312,000 after purchasing an additional 2,079 shares during the period. Howe & Rusling Inc. acquired a new stake in shares of Invesco Pharmaceuticals ETF during the third quarter worth approximately $48,000. FMR LLC grew its position in shares of Invesco Pharmaceuticals ETF by 29.4% during the third quarter. FMR LLC now owns 1,057 shares of the company’s stock worth $92,000 after buying an additional 240 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF during the third quarter worth approximately $402,000. Finally, Jane Street Group LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF during the third quarter worth approximately $1,163,000.

Invesco Pharmaceuticals ETF Trading Up 0.3 %

PJP stock opened at $84.11 on Friday. Invesco Pharmaceuticals ETF has a twelve month low of $75.33 and a twelve month high of $89.87. The company has a market capitalization of $254.85 million, a P/E ratio of 22.36 and a beta of 0.56. The firm has a 50 day simple moving average of $85.18 and a 200-day simple moving average of $85.90.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.